ADC Therapeutics SA (ADCT) Misses Q2 EPS by 13c

ADC Therapeutics SA (NYSE: ADCT) reported Q2 EPS of ($0.95), $0.13 worse than the analyst estimate of ($0.82). Revenue for the quarter came in at $3.76 million versus the consensus estimate of $2.37 million.

“We were thrilled to receive accelerated FDA approval for the first indication for ZYNLONTA™ and are encouraged by the momentum and positive feedback in the initial weeks following approval. We remain highly focused on the successful execution of the launch and positive about the longer-term potential of the product,” said Chris Martin, Chief Executive Officer of ADC Therapeutics. “During the second quarter, we were also pleased to present positive data on ZYNLONTA and our exciting pipeline of advancing programs at key medical meetings. Looking to the rest of the year, we have several notable milestones on the horizon and look forward to keeping you updated on our progress.”

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Vivos Therapeutics posts 35% revenue gain but widens net loss